Vancouver, Canada, April 21, 2025 — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled “Gazing Through the Crystal Ball.” The event is scheduled for May 21, 2025, at 12:00 PM ET (9:00 AM PT) and will feature a distinguished panel of experts discussing the evolving landscape of psychedelic science and business in the context of changing FDA policies and political climates.
For more information: https://www.clearmindmedicine.com/upcoming-events/gazing-through-the-crystal-ball
Featured Speakers Include:
Rick Doblin, PhD – Founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS). A trailblazer in psychedelic-assisted therapy, Dr. Doblin has dedicated his career to establishing safe, legal, and ethical uses of psychedelics through rigorous scientific research.
Robin Carhart-Harris, PhD – Ralph Metzner Distinguished Professor of Neurology and Psychiatry at the University of California, San Francisco (UCSF). Dr. Carhart-Harris is widely recognized for his pioneering work in psychedelic neuroscience and has led several landmark clinical studies on psilocybin and other compounds.
Dr. Adi Zuloff-Shani – Chief Executive Officer of Clearmind Medicine. Dr. Zuloff-Shani brings decades of clinical and regulatory expertise and currently leads the development of Clearmind’s innovative treatment for Alcohol Use Disorder (AUD), CMND-100, which recently advanced into FDA-approved clinical trials.
Mark Haden – VP Business Development of Clearmind. Adjunct Professor at the University of British Columbia School of Population and Public Health and former Executive Director of MAPS Canada. Mr. Haden is a leading voice in drug policy reform and has worked extensively on public health-based approaches to psychedelic regulation and integration.
The panel discussion will be moderated by Shannon Smadella, wellness advocate, executive consultant and podcast host. Ms. Smadella is a recognized voice in the psychedelic space and has played a key role in public engagement and awareness through events, such as World Psychedelics Day and MAPS Canada collaborations.
For additional information or media inquiries, please contact Clearmind at invest@clearmindmedicine.com.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com